Vanguard to raise pounds 47m for research
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Vanguard Medica, the biotech company backed by some of the most famous names in drug discovery, announced it is raising funds worth almost half its market capitalisation for future research. The company is raising pounds 47.9m through a placing and open offer and warrants issue. The shares yesterday closed down 12.5p to 432.5p.
Robert Mansfield, Vanguard's chief executive, said the company, with pounds 33m cash in the bank, needed the money to attract partners for newer projects. "We need to be able to reassure big pharmaceutical companies that we have adequate resources." He said the money would be sufficient for three years' R&D. Vanguard's lead product is an anti-migraine drug, due to be submitted for approval next year, but it is working in other areas, including asthma and psoriasis.
Analysts said that the fund-raising was timely, coming ahead of a likely boom in biotech new issues next year which could drain funds from the market. The fund-raising is being backed by NM Rothschild's Biotechnology Investment Trust, which is investing pounds 6m. In a complex and novel financing, for every 11 shares held, Vanguard investors will buy a unit for 12.15p, comprising three ordinary shares priced at 4.05p and two warrants exercisable at 500p by 11 December 1998.
Vanguard's directors include Sir David Jack, who as head of research at Glaxo was responsible for ulcer treatment Zantac, once the world's biggest selling drug and Sir John Vane, the Nobel prize winner who was formerly head of research and development at Wellcome.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments